Day: April 28, 2021

Selskabsmeddelelse nr. 07/202128. april 2021 Sydbanks delårsrapport – 1. kvartal 2021 Stærk og lovende start på 2021 Hovedpunkter fra regnskabet for 1. kvartal 2021Resultat på 291 mio. kr. giver en egenkapitalforrentning på 9,5 pct. p.a. efter skat Basisindtjeningen på 1.105 mio. kr. er 15 pct. højere end i samme periode i 2020 Basisomkostningerne er 16 pct. højere i forhold til samme periode i 2020 og udgør 833 mio. kr. Nedskrivninger på udlån udgør en indtægt på 81 mio. kr. mod en udgift på 84 mio. kr. i sammeperiode i 2020 Bankudlån udgør 61,5 mia. kr. – en stigning på 1,3 mia. kr. i 1. kvartal 2021 Samlet kreditformidling udgør 168,1 mia. kr. – en stigning på 2,5 mia. kr. i 1. kvartal 2021 Egentlig kernekapitalprocent er faldet med 0,7 procentpoint i forhold til ultimo 2020 og er på 18,1 uden indregning af periodens resultat.Administrerende...

Updated with an E-x date.To approve the reports of the Company’s Management Board and the Supervisory Board on the Annual Report for the Year 2020. To approve the Annual Report for the Year 2020, including the corporate governance report and the remuneration report for members of the Management Board and the Supervisory Board, prepared as separate components of the annual report. To leave the profit of the reporting year 104067.69 EUR undistributed. To pay out the retained earnings of 46468.40 euro, shown in the balance sheet as at December 31, 2017, in dividends, which is 0.11 euro per share. To set the record date for dividend payment: May 19, 2021, and dividend payment date: May 20, 2021. Ex-date: May 18, 2021. To discharge the members of the Management Board, the members of the Supervisory Board and the auditor from responsibility...

Papildināts ar E-x datumu.Apstiprināt akciju sabiedrības valdes un padomes ziņojumus par 2020. gada pārskatu. Apstiprināt Gada pārskatu par 2020. gadu, t. sk. korporatīvās pārvaldības ziņojumu un valdes un padomes atalgojuma ziņojumu, kas sagatavoti kā atsevišķas gada pārskata sastāvdaļas. Pārskata gada peļņu 104067,69 EUR atstāt nesadalītu. Izmaksāt no iepriekšējo gadu nesadalītās peļņas, kura uzrādīta bilancē 2017. gada 31. decembrī, dividendēs 46468,40 eiro, kas ir 0,11 eiro par vienu akciju.  Noteikt ieraksta datumu dividenžu izmaksai: 2021. gada 19. maijs un dividenžu izmaksas datumu: 2021. gada 20. maijs. E-x datums: 2021. gada 18. maijs. Atbrīvot valdes un padomes locekļus, kā arī revidentu no atbildības par darbību 2020. gadā un atteikties no prasību celšanas pret viņiem. Par sabiedrības revidentu ievēlēt zvērinātu revidenti...

Hexagon Composites’ first quarter 2021 results will be released on 12 May 2021, 07:00 CET. Jon Erik Engeset (CEO) and David Bandele (CFO) will present the results at 08:30 CET and the presentation will be broadcasted live. The presentation will be held in English. Link to webcast: https://hexagongroup.kg5.no/ A recording of the presentation will be made available on www.hexagongroup.com after the presentation. For more information: Hiva Ghiri, VP Investor Relations, Hexagon CompositesTelephone: +47 958 66 790 | hiva.ghiri@hexagongroup.com Karen Romer, SVP Communications, Hexagon CompositesTelephone: +47 950 74 950 | karen.romer@hexagongroup.com About Hexagon Composites ASA Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range...

LONDON and BOSTON, April 28, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce positive results of OK-201, a non-opioid analgesic drug candidate, delivered topically in a mouse neuropathic corneal pain model demonstrating its potential to treat acute and chronic ocular pain. The research program involved a key collaboration with Pedram Hamrah, MD, an ophthalmologist, cornea specialist, and Clinician-Scientist at Tufts Medical Center and Professor of Ophthalmology at Tufts University School of Medicine, Boston. The collaborative effort was focused on evaluating OKYO’s lead compounds as potential non-opioid analgesics to suppress neuropathic corneal...

We would like to remind that KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the April 30th of 2021 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Jonas Lenkšas who will introduce the performance and unaudited financial results of KN for the three months of 2021. How to join the webinar?To join the webinar, please register via following link:https://register.gotowebinar.com/register/7211612518603224845 You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can’t be downloaded, a...

Primename, jog š.m. balandžio 30 d. 9.00 val. KN kviečia akcininkus, investuotojus, analitikus ir visus besidominčius į 2021 metų trijų mėnesių neaudituotų finansinių rezultatų pristatymą internetiniame seminare (angl. „webinar“), kuris vyks anglų kalba. Bendrovės 2021 metų trijų mėnesių neaudituotus finansinius rezultatus komentuos ir po prezentacijos į dalyvių klausimus atsakys KN Generalinis direktorius Darius Šilenskis ir Finansų direktorius Jonas Lenkšas. Kaip prisijungti prie internetinio seminaro?Visus norinčius dalyvauti internetiniame seminare, prašome registruotis aktyvuojant šią nuorodą: https://register.gotowebinar.com/register/7211612518603224845 Jums bus išsiųsta nuoroda prisijungti į internetinį seminarą ir instrukcija, kaip sėkmingai tai padaryti. Jungiantis į seminarą pirmą kartą, bus prašoma atsisiųsti nedidelį priedą...

Municipality Finance PlcStock exchange release28 April 2021 at 9:00 am (EET) Municipality Finance issues a GBP 65 million tap under its MTN programme On 29 April 2021 Municipality Finance Plc issues a new tranche in an amount of GBP 65 million to an existing benchmark issued on 17 March 2021. With the new tranche, the aggregate notional amount of the benchmark is GBP 340 million. The maturity date of the benchmark is 17 December 2025. The benchmark bears interest at fixed rate of 0.375% per annum. The new tranche is issued under MuniFin’s EUR 40 billion programme for the issuance of debt instruments. The offering circular and the supplemental offering circular are available in English on the company’s website at www.munifin.fi/investor-relations. MuniFin has applied for the new tranche to be admitted to trading on the Helsinki Stock...

Kuntarahoitus OyjPörssitiedote28.4.2021 klo 9.00 Kuntarahoitus laskee liikkeeseen 65 miljoonan Englannin punnan lisäyksen viitelainaan osana joukkovelkakirjalainaohjelmaa Kuntarahoitus Oyj laskee 29.4.2021 liikkeeseen 65 miljoonan Englannin punnan lisäyksen 17.3.2021 liikkeeseen laskettuun viitelainan. Lisäyksen jälkeen viitelainan koko on 340 miljoonaa Englannin puntaa. Viitelainan eräpäivä on 17.12.2025. Viitelainalle maksetaan vuosittaista korkoa 0,375 %. Viitelainan lisäyksen liikkeeseenlasku tapahtuu yhtiön 40 miljardin euron joukkovelkakirjalainaohjelman alla. Ohjelmaa koskeva esite ja sen täydennys ovat saatavilla englanninkielisinä yhtiön verkkosivuilta osoitteesta www.munifin.fi/investor-relations. Kuntarahoitus on hakenut viitelainan lisäyksen ottamista julkisen kaupankäynnin kohteeksi Nasdaq Helsinki Oy:n pörssilistalle. Julkisen...

OP Corporate Bank plcInterim Report 1 January–31 March 2021Stock Exchange Release 28 April 2021 at 9.00am EEST OP Corporate Bank plc’s Interim Report for 1 January–31 March 2021Consolidated earnings before tax improved to EUR 152 million (27). Total income increased to EUR 367 million (166) and, including the overlay approach, income increased by 38% to EUR 342 million (248). Investment income increased to EUR 87 million (25). Net insurance income increased by 20% to EUR 157 million (131). Net interest income decreased by 5% to EUR 77 million (81). A total of EUR 2 million of impairment loss on receivables were reversed whereas they weakened earnings by EUR 49 million a year ago. Total expenses increased by 12% to EUR 192 million (171). Corporate Banking earnings before tax improved to EUR 101 million (9). Earnings were strengthened...